Posted by Michael Wonder on 29 Jun 2023
Esperion announces submission of application for expanded indication with the EMA for Nilemdo (bempedoic acid) tablet and Nustendi (bempedoic acid and ezetimibe) tablet
28 June 2023 - Seeking inclusion of CV risk reduction indications in Europe.
Esperion today announced that the application was filed for a type II(a) variation with the EMA for the Company’s oral non-statin products marketed as Nilemdo and Nustendi in Europe.
